Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a publicly traded Healthcare sector company. As of May 21, 2026, AMRX trades at $12.45 with a market cap of $3.80B and a P/E ratio of 31.40. AMRX moved +3.39% today. Year to date, AMRX is -3.78%; over the trailing twelve months it is +64.82%. Its 52-week range spans $6.69 to $15.42. Analyst consensus is strong buy with an average price target of $17.25. Rallies surfaces AMRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Amneal Q1 Revenue $723M Up 4%, Specialty Segment Grows 23%: Amneal Pharmaceuticals posted first-quarter net revenue of $723 million, up 4%, with GAAP net income surging 411% to $62 million and diluted EPS of $0.19. Specialty revenue climbed 23%, driving adjusted EBITDA to $202 million and the company reaffirmed full-year guidance of $3.05–3.15 billion revenue and $0.95–1.05 EPS.
| Metric | Value |
|---|---|
| Price | $12.45 |
| Market Cap | $3.80B |
| P/E Ratio | 31.40 |
| EPS | $0.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.42 |
| 52-Week Low | $6.69 |
| Volume | 1.20M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.05B |
| Net Income | $181.31M |
| Gross Margin | 38.66% |
5 analysts cover AMRX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.25.